Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,420,000 shares, a drop of 21.5% from the November 30th total of 1,810,000 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average trading volume of 4,630,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its holdings in Athira Pharma by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock worth $1,458,000 after buying an additional 111,759 shares during the period. GSA Capital Partners LLP grew its position in Athira Pharma by 909.8% during the third quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock valued at $177,000 after buying an additional 357,787 shares during the period. Bristlecone Advisors LLC raised its position in shares of Athira Pharma by 295.6% in the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock worth $151,000 after acquiring an additional 252,200 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares in the last quarter. Finally, Forefront Analytics LLC raised its holdings in Athira Pharma by 126.0% in the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares during the period. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Trading Up 2.1 %

NASDAQ ATHA opened at $0.55 on Friday. Athira Pharma has a 12-month low of $0.41 and a 12-month high of $4.30. The firm’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $1.58. The firm has a market capitalization of $21.26 million, a P/E ratio of -0.19 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.05. As a group, sell-side analysts predict that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ATHA. Mizuho cut Athira Pharma from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $5.00 to $0.50 in a research report on Thursday, September 19th. JMP Securities cut shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th. BTIG Research lowered Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. Finally, Rodman & Renshaw downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.